Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 23.67 kDa 
• Atom Count: 1766 
• Modelled Residue Count: 207 
• Deposited Residue Count: 208 
• Unique protein chains: 1

4LWI

Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ6

• DOI: 10.2210/pdb4LWI/pdb

• Classification: CHAPERONE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2013-07-27 Released: 2014-07-30 
• Deposition Author(s): Li, J., Shi, F., Xiong, B., He, J.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.70 Å
• R-Value Free: 0.213 
• R-Value Work: 0.191 
• R-Value Observed: 0.192 

Literature

Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors.

Chen, D., Shen, A., Li, J., Shi, F., Chen, W., Ren, J., Liu, H., Xu, Y., Wang, X., Yang, X., Sun, Y., Yang, M., He, J., Wang, Y., Zhang, L., Huang, M., Geng, M., Xiong, B., Shen, J.

(2014) Eur J Med Chem 87: 765-781

• PubMed: 25313505 
• DOI: 10.1016/j.ejmech.2014.09.065
• Primary Citation of Related Structures:  
  4LWG, 4LWH, 4LWI, 4LWE, 4LWF


• PubMed Abstract: 
  

HSP90 is ubiquitously overexpressed in a broad spectrum of human cancers and has been recognized as an attractive target for cancer treatment. Here, we described the fragment screening, synthesis and structure-activity relationship studies of small molecule inhibitors with 4,5-diarylisoxazole scaffold targeting HSP90. Among them, the compound N-(3-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-((4-morpholinopiperidin-1-yl)methyl)phenyl)isoxazol-5-yl)cyclopropanecarboxamide (108) showed high affinity for binding to HSP90 (FP binding assay, IC50 = 0.030 μM) and inhibited the proliferation of various human cancer cell lines with averaging GI50 about 88 nM. Compound 108 exhibited its functional inhibition of HSP90 by depleting key signaling pathways and concomitantly elevating of HSP70 and HSP27 in U-87MG cells. Further in vivo studies showed that compound 108 strongly suppressed the tumor growth of human glioblastoma xenograft model U-87MG with T/C = 18.35% at 50 mg/kg q3w/2.5w. Moreover, compound 108 also exhibited good pharmacokinetic properties. Together, our study implicates that compound 108 is a promising candidate of HSP90 inhibitor and is currently advanced to preclinical study.

---

Organizational Affiliation: 

Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China. Electronic address: [e-mail].

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Heat shock protein HSP 90-alpha	A	208	Homo sapiens	Mutation(s): 0  Gene Names: HSP90AA1, HSP90A, HSPC1, HSPCA
UniProt & NIH Common Fund Data Resources
Find proteins for P07900 (Homo sapiens) Explore P07900  Go to UniProtKB:  P07900
PHAROS:  P07900 GTEx:  ENSG00000080824

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
FJ6	B [auth A]	N-{3-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(4-methoxyphenyl)-1,2-oxazol-5-yl}cyclopropanecarboxamide C23 H24 N2 O5 AVNWJTBEPNSVIJ-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
FJ6	IC50:  23   nM  BindingDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.70 Å
• R-Value Free: 0.213 
• R-Value Work: 0.191 
• R-Value Observed: 0.192 
• Space Group: I 2 2 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 65.666	α = 90
b = 89.256	β = 90
c = 99.715	γ = 90

Software Package:

Software Name	Purpose
HKL-2000	data collection
PHENIX	model building
PHENIX	refinement
HKL-2000	data reduction
HKL-2000	data scaling
PHENIX	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2013-07-27 
• Released Date: 2014-07-30 
Deposition Author(s): Li, J., Shi, F., Xiong, B., He, J.

Revision History  

• Version 1.0: 2014-07-30
  Type: Initial release
  
• Version 1.1: 2016-10-12
  Changes: Database references